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Background: The purpose of this study was to investigate the impact of treatment with tran-
scatheter arterial chemoembolization on the expression of chemokine receptors on memory 
T cells around tumor sites in vivo in patients with hepatocellular carcinoma.
Methods: Blood samples from the hepatic artery and a peripheral vein were collected from 
100 patients with hepatocellular carcinoma before and 4 weeks after treatment with transcatheter 
arterial chemoembolization. Mononuclear cells were isolated and examined for the expression 
of L-selectin (CD62L) and CXCR3 (CD183) on CD8+ T cells in patients with hepatocellular 
carcinoma during transcatheter arterial chemoembolization.
Results: Both the frequency and number of L-selectinlow CXCR3+ proinflammatory effector 
T cells in patients with hepatocellular carcinoma increased significantly following treatment 
versus pretreatment (61.92% ± 8.69% versus 24.45% ± 7.36%, P , 0.05, and 18.98 ± 2.33 e7/L 
versus 6.10 ± 1.21 e7/L, P , 0.001, respectively). There was no significant difference in its 
frequency whether in the hepatic artery or peripheral vein. Furthermore, the frequency of 
CD69+ T cells in patients with hepatocellular carcinoma increased from 2.53% ± 0.51% in 
the artery and 2.38% ± 0.49% in the vein to 3.80% ± 0.62% and 4.48% ± 0.75%, respectively, 
after treatment (both P , 0.05).
Conclusion: Treatment with transcatheter arterial chemoembolization may lead to an increase 
in L-selectinlow CXCR3+ effector T cells in patients with hepatocellular carcinoma.
Keywords: hepatocellular carcinoma, transcatheter arterial chemoembolization, T cells, 
L-selectin, CXCR3
Introduction
Hepatocellular carcinoma is a major health problem worldwide and responsible 
for approximately one million deaths annually.1–3 Recent advances in therapy have 
improved survival rates,4 but little is known about the underlying immune   mechanism. 
T lymphocytes are believed to constitute the main body of effectors in active 
immune protection against cancer. Paradoxically, many patients with detectable 
tumor   antigen-specific T cells in their peripheral blood lymphocytes still continue to 
progress, suggesting that the existence of peripheral tumor-specific CD8+ effector 
cells alone may be insufficient to mediate immunologic control of tumors. One pos-
sibility is that many of the activated T cells fail to home to tumor sites. Accessibility 
of T cells to tumor compartments requires specific interactions between lymphocyte 
cell surface receptors, selectins, and integrins on the vascular epithelium, as well as 
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between lymphocyte-expressed CC or CXC chemokine 
receptors and soluble chemokines derived from host tissues 
near the tumor or from the tumor itself. Likewise, success-
ful T cell-mediated antitumor immunotherapy may rely on 
expression of CXC chemokine receptors on lymphocytes. 
L-selectin (CD62L) is a crucial adhesion molecule that 
regulates both migration of leukocytes at sites of inflam-
mation and recirculation of lymphocytes between blood 
and lymphoid tissues. Chemokine (C-X-C motif) receptor 
3 (CXCR3) is upregulated on   activated T cells and plays 
a critical role in recruiting effector and effector memory 
T cells to enter peripheral inflammation tissue. High levels of 
CXCR3 (CD183) on circulating and tumor-infiltrating CD8+ 
T cells have recently been implicated in effective control 
of advanced melanoma5,6 and achievement of viral control 
in both chronic hepatitis B and C.7,8 An increasing number 
of studies have demonstrated that L-selectinlow CXCR3+ 
proinflammatory effector T cells facilitate the tissue inflam-
matory reaction.9,10 To date, no study has characterized the 
role of CXC chemokine receptors on activated T cells in vivo 
when treating hepatocellular carcinoma with transcatheter 
arterial chemoembolization. Given that transcatheter arterial 
chemoembolization leads to necrosis of tumor tissue, we 
hypothesized that p  roinflammatory molecules released from 
necrotic cells would stimulate proinflammatory L-selectinlow 
CXCR3+ effector T cells and encourage the inflammatory 
reaction. Therefore, in the present study, we investigated 
the impact of transcatheter arterial chemoembolization on 
expression of chemokine receptors on memory T cells around 
tumor sites in patients with hepatocellular carcinoma.
Materials and methods
This study was carried out in accordance with the Declara-
tion of Helsinki and was approved by the ethics committee 
of Capital Medical University. All patients provided their 
informed written consent.
Patient selection
Between January 2010 and December 2010, 100 patients with 
hepatocellular carcinoma (86 men, 14 women) aged 51 ± 12 
(range 21–78) years with no indication for surgical resection 
were enrolled in the study. Ten healthy volunteers, aged 
20–38 years, were recruited from Capital Medical University. 
Hepatocellular carcinoma was diagnosed by distinctive find-
ings on ultrasonography, computed tomography, magnetic 
resonance imaging, and angiography, and serum levels of 
alpha-fetoprotein. After being shown the results of previous 
clinical studies of transcatheter arterial chemoembolization, 
all 100 patients selected this therapeutic option on the basis 
of informed consent. All of the enrolled patients met the 
eligibility criteria for inclusion in the analysis, as described 
in the next paragraph.
Transcatheter arterial chemoembolization 
procedure
Initially, selective angiography was carried out in all 
patients. After identifying the tumor-feeding artery, tran-
scatheter hepatic segmental arterial chemoembolization 
using anticancer drugs was performed comprising 1000 mg 
of 5-fluorouracil, 20 mg of hydroxycamptothecin cisplatin 
or 10–20 mg of mitomycin C, and then 5–20 mL ethiodized 
oil (lipiodol, André Guerbet, Aulnay-sous-bois, France), 
followed by injection of Gelfoam particles. The mixture of 
lipiodol and anticancer drugs was selectively infused into 
the hepatic vessels supplying tumor-bearing tissue until the 
lipiodol was thickly accumulated in the tumor tissue and 
tumor-bearing area. The arteries were then embolized using 
gelatin sponge particles. The volume of injected lipiodol 
in each patient was 2–30 mL according to tumor size, vas-
cularity, and fluoroscopic findings. Transcatheter arterial 
chemoembolization treatment was repeated if there was any 
residual tumor detected after 4 weeks.
Blood collection and preparation  
of mononuclear cells
After identifying the tumor-feeding artery, 10 mL of blood 
from the hepatic artery and 10 mL of blood from a peripheral 
vein was collected from the same patients.   Mononuclear 
cells were prepared from freshly drawn blood using stan-
dard Ficoll-Paque (Gibco, Grand Island, NY) density 
gradient centrifugation. The cells were washed twice with 
sterile phosphate-buffered saline and resuspended in com-
plete RPMI 1640 medium (Gibco) containing 2 mmol/L 
L-glutamine (Gibco), 10% (vol/vol) heat-inactivated 
fetal calf serum (Gibco), 100 IU/mL of penicillin, and 
100 µg/mL of streptomycin (Gibco). The cell concentration 
in the final suspension was 1.0–2.0 × 106 cells/mL.
Multiparametric phenotypic 
characterization of T subsets
Assays were performed on freshly isolated mononuclear 
cells. For phenotypic analysis, one million mononuclear cells 
were stained with freshly prepared antibodies, ie, fluores-
cently labeled CD3-PeCy7, CD8-fluorescein isothiocyanate, 
L-selectin phycoerythrin, and CXCR3-PeCy5 for 30 minutes 
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at 4°C in the dark. Staining was performed in a final volume 
of 100 µL. All antibodies were titered beforehand to achieve 
optimum results. Following a final wash step, the cells were 
resuspended in 1% paraformaldehyde.
Flow cytometry analysis
All data were acquired on a FC500 flow cytometer instru-
ment within 8 hours of staining and was analyzed using CXP 
Cytometer software (Beckman Coulter Inc, Fullerton, CA). 
The cells were gated initially on lymphocytes as determined 
by forward and side scatter, and where possible, data from 
at least 100,000 small lymphocytes were collected. For 
most samples, 10,000 to 20,000 CD3+ CD8+ T cells were 
collected for analysis.
Quantitation of L-selectinlow CXCR3+ 
effector T cells
The number of total lymphocytes per liter (N) was analyzed 
on an XE2100 automatic blood cell analyzer. The frequency 
of L-selectinlow CXCR3+ proinflammatory effector T cells (F) 
was acquired by flow cytometry. The number of L-selectinlow 
CXCR3+ proinflammatory effector T cells per liter (T) was 
calculated as follows: T = N × F.
Statistical analysis
The mean and standard deviation were used to describe the 
samples. Analyses were performed using SPSS version 13.0 
(SPSS Inc, Chicago, IL). Significant differences between 
patients and healthy volunteers were assessed using one-way 
analysis of variance and least squares difference for post hoc 
multiple comparisons. Differences between pretreatment and 
post treatment for arterial and venous samples were analyzed 
using the paired-sample t-test. All mononuclear cell samples 
were blinded as to the source of cells. Information on study 
participants was compiled only after all the experiments were 
completed and the data were prepared for analysis.
Results
To analyze the influence of transcatheter arterial chemoem-
bolization on expression of L-selectin and CXCR3 on T cells, 
we first compared the phenotype of CD8 T cells in patients 
with hepatocellular carcinoma prior to treatment with that of 
healthy controls. In patients with hepatocellular carcinoma, 
L-selectin-CXCR3+ effector T cells dominated in the periph-
eral vein, with a vast majority of 74.47% ± 9.36% compared 
with L-selectinhigh CXCR3- and L-selectinlow CXCR3+ 
T cells. In contrast, the frequency of L-selectinhigh CXCR3- 
proliferative T cells was 52.78% ± 11.83% in a healthy vol-
unteer, significantly higher than that of L-selectinlow CXCR3+ 
T cells (17.51% ± 5.91%), and L-selectin-CXCR3+ T cells 
(17.02% ± 7.49%, P , 0.05, Figure 1).
Next, we tracked changes in L-selectin and CXCR3 
expression on T cells after transcatheter arterial chemoem-
bolization. The frequency of L-selectinlow CXCR3+ T cells 
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Figure 1 Comparison of expression of L-selectin and CXCR3 on CD8 T cells between patients with hepatocellular carcinoma and healthy volunteers.
Notes: In patients with hepatocellular carcinoma, the frequency was 0.6% ± 0.25% for L-selectinhigh CXCR3- T cells, 24.45% ± 7.36% for L-selectinlow CXCR3+ T cells, and 
74.47% ± 9.36% for L-selectin-CXCR3+ T cells. The proportion of L-selectin-CXCR3+ T cells was significantly higher than that of the other two subsets (both P , 0.05). In contrast, 
the frequency of L-selectinhigh CXCR3- T cells in healthy volunteers was 52.78% ± 11.83%, significantly (P , 0.05) higher than for L-selectinlow CXCR3+T cells (17.51% ± 5.91%) and 
L-selectin-CXCR3+ T cells (17.02% ± 7.49%). In patients with hepatocellular carcinoma, the frequency of L-selectinlow CXCR3+ T cells increased to 61.92% ± 8.69% posttreatment, 
which was significantly higher than the 24.45% ± 7.36% value pretreatment (P , 0.05); the percentage of L-selectinhigh CXCR3- T cells posttreatment remained unchanged, while 
L-selectin-CXCR3+ T cells decreased from 74.47% ± 9.36% to 39.08% ± 11.46%. The mean value ± standard deviation of percentage of T cells is shown.
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increased to 61.92% ± 8.69% after treatment, which was 
significantly higher than before treatment (P , 0.05, 
  Figure 1), while L-selectin-CXCR3+ T cells decreased 
from 74.47% ± 9.36% to 39.08% ± 15.46%. The proportion 
of L-selectinhigh CXCR3- T cells remained unchanged. It is 
suspected that as one cell population increases, the other 
decreases, and vice versa. Because of this limitation, it is dif-
ficult to determine which event, ie, an increase in L-selectinlow 
CXCR3+ T cells or a decrease in L-selectin-CXCR3+ T cells, 
is the initial one. Therefore, we analyzed absolute numbers 
of T cells to confirm the above observation.   Similar to the 
percentages, the absolute number of L-selectinlow CXCR3+ 
T cells after treatment increased to 18.98 ± 2.33 e7/L, which is 
significantly more than the 6.10 ± 1.21 e7/L prior to treatment 
(P , 0.001). L-selectin-CXCR3+ T cells wavered between 
13.79 ± 3.78 e7/L pretreatment and 13.68 ± 2.47 e7/L 
after treatment, and L-selectinhigh CXCR3- T cells from 
0.13 ± 0.06 e7/L to 0.87 ± 0.25 e7/L, respectively, with no 
significant difference between pretreatment and post treat-
ment values (Figure 2).
It was unclear whether the amounts of L-selectinlow 
CXCR3+ T cells increased because of redistribution caused 
by transcatheter arterial chemoembolization. To address 
this issue, we examined the expression of CXCR3 and 
L-selectin on T cells in the peripheral vein and in the hepatic 
artery. The frequency of L-selectinhigh CXCR3- T cells in the 
hepatic artery and the peripheral vein was 11.31% ± 10.92% 
and 12.55% ± 12.4%, respectively, the frequency of 
L-selectinlow CXCR3+ T cells was 22.64% ± 12.63% and 
21.85% ± 13.61%, and the frequency of L-selectin-CXCR3+ 
T cells was 45.25% ± 12.45% and 44.25% ± 13.77%, respec-
tively (Figure 3). There was no significant difference in T cell 
phenotype between the artery and the vein.
It could be that transcatheter arterial chemoembolization 
induced proliferation and differentiation of T cells. Therefore, 
we next tested CD69 expression on T cells. The frequency 
of CD69+ T cells before treatment was 2.53% ± 0.51% in 
the artery and 2.38% ± 0.49% in the vein, respectively, and 
post treatment was 3.80% ± 0.62% and 4.48% ± 0.75%, 
respectively (Figure 4). The proportion of activated T cells 
after treatment was significantly higher than that before in 
both the artery and the vein (P , 0.05). Interestingly, there 
was no significant difference between their frequency in the 
artery and vein before and after treatment.
Discussion
Transcatheter arterial chemoembolization improves survival 
in patients with hepatocellular carcinoma, for whom curative 
therapies are not available. However, so far, the underlying 
immune mechanism is still unclear. Our study affords a lon-
gitudinal observation of the alteration of subsets of memory 
T cells during transcatheter arterial chemoembolization. In 
healthy volunteers, L-selectinhigh CXCR3- proliferative T cells 
were present in considerably higher proportions than was 
the effector subset of cells, suggesting a powerful potential 
to proliferate, expand, and maintain immune homeostasis 
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25
20
15
10
5
0
L-selectinhigh CXCR3- T
Pretreatment Posttreatment
L-selectinlow CXCR3+ T L-selectin-CXCR3+ T
N
u
m
b
e
r
 
o
f
 
T
 
c
e
l
l
s
 
(
∗
1
0
e
7
/
1
)
Figure 2 Change in the absolute number of L-selectinlow CXCR3+ T cells before and after transcatheter arterial chemoembolization.
Notes: In patients with hepatocellular carcinoma, the number of L-selectinlow CXCR3+ T cells posttreatment was 18.98 ± 2.33 e7/L, which is significantly more than the 
6.10 ± 1.21 e7/L prior to treatment (P , 0.001), L-selectin-CXCR3+ T cells changed slightly from 13.79 ± 3.71 e7/L pretreatment to 13.68 ± 2.47 e7/L after treatment, and 
L-selectinhigh CXCR3- T cells from 0.13 ± 0.06 e7/L to 0.87 ± 0.25 e7/L, respectively, with no significant difference between pretreatment and posttreatment. The mean 
value ± standard deviation of number of T cells is shown.
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upon encountering an antigen challenge, given that naive 
T cells and central memory T cells in a steady-state home 
to high endothelial venules and T cell areas in secondary 
lymphoid tissue via expression of the L-selectin molecule.11 
In contrast, the frequency of L-selectin-CXCR3+ effector 
T cell subsets was higher in patients with hepatocellular 
carcinoma before treatment. However, both the absolute 
numbers and proportions of L-selectinlow CXCR3+ proin-
flammatory T cell subsets increased markedly post treat-
ment compared with pretreatment, being consistent with 
our recent finding that patients with chronic hepatitis B and 
a viral response showed a significantly higher proportion of 
CXCR3+CD8+ T cells pretreatment and at 24 weeks.8 An 
increase in L-selectinlow CXCR3+ proinflammatory effector 
T cell subsets may be due to two factors, one of which may 
involve the T cell   compartment. However, interestingly, there 
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Figure 3 CXCR3 and L-selectin expression on T cells in the peripheral vein and the hepatic artery.
Notes: In patients with hepatocellular carcinoma, the frequency of L-selectinhigh CXCR3- T cells was 11.31% ± 10.92% and 12.55% ± 12.4% in the artery and vein, and of 
L-selectinlow CXCR3+ T cells was 22.64% ± 12.63% and 21.85% ± 13.61% in the artery and vein, respectively. There was no significant difference in the phenotype of T cells 
between the artery and the vein. The mean value ± standard deviation of percentage of T cells is shown.
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Figure 4 Comparison of CD69 expression on T cells before and after treatment.
Notes: The frequency of CD69+ T cells in patients with hepatocellular carcinoma before treatment was 2.53% ± 0.51% and 2.38% ± 0.49% in the artery and vein, and 
posttreatment was 3.80% ± 0.62% and 4.48% ± 0.75%, respectively. The proportion of activated T cells posttreatment was significantly higher than that before treatment, both 
in the artery and the vein (P , 0.05). There was no significant difference between its frequency in the artery and vein before or after treatment. The mean value ± standard 
deviation of percentage of T cells is shown.
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was no   significant difference in the frequency of T cell sub-
sets between the peripheral vein and the hepatic artery, indi-
cating that the higher proportion of the L-selectinlow CXCR3+ 
T cell subset posttreatment did not come from redistribution 
of T cells, which is in agreement with the finding of Thimme 
et al that the frequency of alpha-fetoprotein-specific CD8 
T cells in the livers of patients with hepatocellular carci-
noma was not higher than in peripheral blood.12 The other 
factor may be T cell proliferation. Necrosis resulting from 
chemoembolization can lead to stimulation of immunity13–17 
because necrotic cells release proinflammatory molecules, 
such as high mobility group box protein, uric acid, and heat 
shock protein 70, which can trigger dendritic cells to mature. 
Mature dendritic cells stimulate CD4+ T cells to provide help 
for CD8+ T cells, encouraging their expansion into effector 
cells. Moreover, inflammatory stimuli produced by necrotic 
tissue are able to induce high endothelial venule luminal 
CXCR3 ligands and L-selectin ligand expression quickly 
in the high endothelial venule lumen in reactive nodes,18,19 
thus L-selectinlow CXCR3+ proinflammatory CD8+ T cells 
preferentially traffic to reactive nodes, where they undergo 
homeostatic proliferation to boost T numbers.20
Furthermore, enhanced frequency of T cells expressing 
the CD69 molecule following treatment further demonstrated 
that amounts of activated T cells increased post transcath-
eter arterial chemoembolization. Once expressed, CD69 
acts as a costimulatory molecule for T cell activation and 
proliferation.21 Increasing evidence has demonstrated that 
the phenotype of memory T cells can alter due to activation, 
homeostasis, and recirculation.8,22,23 L-selectin expression on 
memory T cell subsets seems to be interconvertible, with 
L-selectinhigh cells losing L-selectin expression following anti-
gen activation or in response to homeostatic cytokines.24–26 It 
is also known that stimulation with CXCL12 induces a spatial 
association between CXCR4 and the T cell receptor complex, 
allowing the chemokine receptor to activate components 
of the T cell receptor signaling pathway, which results in 
increased CD69 and interleukin-2 production,27 and a similar 
utilization of the T cell receptor signaling pathway has been 
shown for CXCR3.28 Stimulation of CXCR3 on the surface 
of activated T cells produces signals which can synergize 
with those transduced by activation of the T cell receptor 
complex. These signals enhance both T cell proliferation 
and specific migration of T cells across cytokine-activated 
endothelium.29
Here we present the alteration of L-selectin and CXCR3 
expression on CD8+ T cells in the process of transcatheter 
arterial chemoembolization. The amounts of L-selectinlow 
CXCR3+ proinflammatory effector T cells increase sig-
nificantly following treatment with transcatheter arterial 
chemoembolization. Because successful immunotherapy to 
a large extent seems to be reduced to the issue of creating 
an appropriate inflammatory reaction, an increase in proin-
flammatory L-selectinlow CXCR3+ T cells may be one of the 
factors critical to induction of tumor immunity.
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